Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Naiyer Rizvi
Thoracic Oncology and Immunotherapeutics, Columbia University Hospital
Study ChairKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tom Baker Cancer Centre
Calgary, Alberta, Canada
- Bcca - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
- Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
- University Health Network
Toronto, Ontario, Canada
- Columbia University Medical Center
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Mar 2019
- Primary completion
- 1 Jun 2021
- Completion
- 9 Feb 2022
- Last update posted
- 22 Feb 2024
- Registered enrollment
- 4
- Registry id
- NCT03461952
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.